Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Biotech & pharma
DURHAM, N.C., Aug. 26, 2026 -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.
Aug 26 · 15:11·GlobeNewswire
Healthcare · Biotech & pharma
Moffitt Cancer Center's Dr. Lary Robinson discusses blood-based biomarkers in early lung cancer detection and ongoing CIZ1B clinical study WASHINGTON, Aug. 26, 2026 -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today...
Aug 26 · 15:00·PR Newswire
SaaS · Healthcare
NCQA evaluated Thyme Care's cancer programs against two separate sets of national standards, covering care planning and monitoring, data integration, staff licensure and training. NASHVILLE, Tenn., Aug. 26, 2026 -- Thyme Care, the oncology company aligning accountability...
Aug 26 · 15:00·PR Newswire
Biotech & pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Regeneron to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the...
Aug 26 · 14:47·Newsfile
Finance · Biotech & pharma
New York, New York--(August 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
Aug 26 · 14:20·Newsfile
Healthcare · Food & drink
LONDON, August 26, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg.
Aug 26 · 14:14·Business Wire
Finance · Biotech & pharma
LEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled "Neoadjuvant botensilimab/balstilimab for localized mismatch re
Aug 26 · 14:05·Business Wire
Biotech & pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Capricor to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Capricor Therapeutics, Inc. ("Capricor" or the...
Aug 26 · 13:56·Newsfile
Biotech & pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in ARS Pharmaceuticals to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals"...
Aug 26 · 13:49·Newsfile
Finance · Healthcare
NEEDHAM, Mass., Aug. 26, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.
Aug 26 · 12:05·GlobeNewswire
AI · Healthcare
SEATTLE and RICHMOND, BC, Aug. 26, 2026 -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's...
Aug 26 · 12:02·PR Newswire
AI · SaaS
MIAMI, Aug. 26, 2026 -- PharmaForceIQ has today introduced Optichannel 360, an AI-native commercial execution platform that connects field and digital marketing, including a new measurement answer-to-action workflow. The Optichannel 360 platform is built as a broader...
Aug 26 · 12:00·PR Newswire